BC expressing hormone receptor (estrogen receptor (ER+) or progesterone receptor (PR+)), BC expressing human epidermal receptor 2 (HER2+), and triple-negative breast cancer (TNBC) (ER−, PR−, HER2−) has been categorized based on histological evidence [4]. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.